IXICO PLC — Regulatory Filings 2016

Oct 3, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2404L

IXICO plc

03 October 2016

Appointment of Shore Capital as Nominated Adviser & Sole Broker

3 October 2016, IXICO plc (AIM: IXI), the brain health company, is pleased to announce the appointment of Shore Capital and Corporate Limited as Nominated Adviser and Shore Capital Stockbrokers Limited as sole Broker, (together "Shore Capital"), with immediate effect.

For further information please contact:

IXICO plc Derek Hill, Chief Executive Officer  Susan Lowther, Chief Financial Officer	Tel: +44 20 3763 7499
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield	Tel: +44 20 7408 4090
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan/Matthew Moss	Tel: +44 20 3727 1000

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGMGZLDLLGVZM